Application

Apolipoprotein C-III (APOC3), human has been used to determine its effect reconstituted high-density lipoprotein (rHDL) containing apoA-I. It has also been used to test the effects of the exogenous exchangeable apolipoproteins on low-density lipoprotein (LDL) binding to heparin.

Biochem/physiol Actions

The physiological role of Apo CIII is unknown. It is suggested that Apo CIII may inhibit the activation of lipoprotein lipase by Apo CII.

Apolipoprotein C-III (APOC3) is involved in triglyceride metabolism and atherosclerotic lesion formation. It also regulates pathological processes involved in atherosclerosis. APOC3 stimulates hypertriglyceridemia (HTG) through various mechanisms. It functions as a lipoprotein lipase (LPL) inhibitor and also interrupts the clearance of triglyceride-rich lipoproteins (TRLs)-remnants. Mutations in the gene lead to lower plasma glycerides and lower cardiovascular disease risk.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Product Source: Human plasma tested negative for HBsAg and HIV-I, HIV-II, HBc and Hepatitis C antibodies. All blood products should be treated as potentially infectious.

Apolipoprotein C-III (APOC3) is a multifaceted protein, localized on circulating triglyceride-rich lipoproteins (TRLs), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL). The APOC3 gene is mapped to the human chromosome 11q23.3. It is mainly expressed in hepatocytes and to a lesser extent in enterocytes.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Liquid in 10 mM NH4HCO3, pH 7.4.

Storage and Stability

Maintain at -20°C or below in undiluted aliquots for up to 12 months. Avoid repeated freeze/thaw cycles. All blood products should be treated as potentially infectious.